US-based medical equipment supplier Vivalink has launched a new adhesive for its wearable electrocardiogram (ECG) sensors to enhance ambulatory cardiac monitoring.
The new adhesive is said to improve p-wave detection by up to 160%, helping clinicians in identifying atrial abnormalities.
P-wave detection is crucial for preventing adverse cardiac events, such as atrial fibrillation, ischemic stroke, and even sudden cardiac death.
The new adhesive is designed using Vivalink’s patented eSkin technology for enhanced comfort, flexibility and superior patient experience.
It complements the company’s multi-vital ECG patch, a lightweight, rechargeable device designed for continuous monitoring in various healthcare settings.
Also, the adhesive supports earlier intervention, better patient outcomes and high-quality data collection in clinical research, said Vivalink.
Vivalink CEO Jiang Li said: “Continual innovation in wearable monitoring technology is at the core of our mission.
“By improving p-wave signal clarity, this new adhesive advances the accuracy and reliability of cardiac monitoring.
“The result is better support for clinicians in identifying arrhythmias early, while easing the burden on patients through comfortable, long-term use in ambulatory settings, hospital-at-home programs and clinical trials that demand accurate ECG data.”
With a water-resistant, contoured design, the new adhesive features a modified lead one placement to boost p-wave visibility.
It has been validated for use in both remote and in-person clinical trials.
The single-use design of the adhesive facilitates a seven-day wear period, ensuring continuous and reliable cardiac monitoring.
Also, it enhances the reliability of clinical trial data and supports effective clinical decision-making in detecting arrhythmias and atrial fibrillation, said Vivalink.
